Neuland Laboratories Limited
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
Key metrics
Price as of 2026-07-17
Stock price
₹18434.00
Market cap
23,781 Cr
Stock P/E
60.9
P/B
12.69
Dividend yield
0.1%
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 363 Cr | 781 Cr | 1,174 Cr | 1,559 Cr | 440 Cr | 750 Cr | 398 Cr | 328 Cr | 293 Cr | 514 Cr | 440 Cr | 776 Cr |
| Operating expenses (approx.) | 264 Cr | 541 Cr | 811 Cr | 1,083 Cr | 291 Cr | 535 Cr | 252 Cr | 270 Cr | 250 Cr | 357 Cr | 355 Cr | 456 Cr |
| EBITDA | 99 Cr | 239 Cr | 363 Cr | 475 Cr | 149 Cr | 215 Cr | 146 Cr | 59 Cr | 42 Cr | 157 Cr | 85 Cr | 320 Cr |
| OPM % | 27.3% | 30.7% | 30.9% | 30.5% | 33.8% | 28.7% | 36.8% | 17.8% | 14.5% | 30.6% | 19.4% | 41.2% |
| Other income | 2 Cr | 5 Cr | 7 Cr | 13 Cr | 5 Cr | 9 Cr | 4 Cr | 7 Cr | 8 Cr | 2 Cr | 8 Cr | 12 Cr |
| Interest | 2 Cr | 7 Cr | 10 Cr | 14 Cr | 3 Cr | 4 Cr | 2 Cr | 2 Cr | 5 Cr | 5 Cr | 7 Cr | 7 Cr |
| Depreciation | 14 Cr | 28 Cr | 43 Cr | 60 Cr | 16 Cr | 32 Cr | 16 Cr | 17 Cr | 20 Cr | 23 Cr | 24 Cr | 25 Cr |
| Profit before tax | 83 Cr | 205 Cr | 309 Cr | 401 Cr | 130 Cr | 179 Cr | 128 Cr | 39 Cr | 18 Cr | 129 Cr | 54 Cr | 287 Cr |
| Tax % | 25.6% | 26.2% | 24.8% | 25.2% | 24.6% | 27.1% | 20.5% | 29.2% | 20.9% | 25.2% | 25.5% | 26.0% |
| Net profit | 62 Cr | 151 Cr | 233 Cr | 300 Cr | 98 Cr | 131 Cr | 102 Cr | 28 Cr | 14 Cr | 97 Cr | 41 Cr | 213 Cr |
| EPS (₹) | ₹48.23 | ₹117.79 | ₹181.23 | ₹233.89 | ₹76.28 | ₹101.88 | ₹79.18 | ₹21.67 | ₹10.83 | ₹75.49 | ₹31.62 | ₹165.76 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2019 | Mar 2020Standalone only | Mar 2021Standalone only | Mar 2022Standalone only | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 667 Cr | 763 Cr | 937 Cr | 951 Cr | 1,191 Cr | 1,559 Cr | 1,477 Cr | 2,023 Cr | Sign in for TTM |
| Operating expenses (approx.) | 608 Cr | 657 Cr | 774 Cr | 806 Cr | 919 Cr | 1,096 Cr | 1,057 Cr | 1,418 Cr | Sign in for TTM |
| EBITDA | 58 Cr | 106 Cr | 163 Cr | 145 Cr | 272 Cr | 463 Cr | 420 Cr | 605 Cr | Sign in for TTM |
| OPM % | 8.8% | 13.9% | 17.4% | 15.2% | 22.8% | 29.7% | 28.5% | 29.9% | Sign in for TTM |
| Other income | 3 Cr | 4 Cr | 16 Cr | 2 Cr | 10 Cr | 13 Cr | 21 Cr | 30 Cr | Sign in for TTM |
| Interest | 16 Cr | 22 Cr | 18 Cr | 13 Cr | 13 Cr | 14 Cr | 8 Cr | 24 Cr | Sign in for TTM |
| Depreciation | 26 Cr | 31 Cr | 40 Cr | 49 Cr | 53 Cr | 60 Cr | 66 Cr | 92 Cr | Sign in for TTM |
| Profit before tax | 20 Cr | 53 Cr | 105 Cr | 82 Cr | 216 Cr | 401 Cr | 346 Cr | 489 Cr | Sign in for TTM |
| Tax % | 19.2% | 69.4% | 23.5% | 22.3% | 24.2% | 25.2% | 24.9% | 25.6% | Sign in for TTM |
| Net profit | 16 Cr | 16 Cr | 81 Cr | 64 Cr | 164 Cr | 300 Cr | 260 Cr | 364 Cr | Sign in for TTM |
| EPS (₹) | ₹13.06 | ₹12.63 | ₹62.85 | ₹49.74 | ₹127.45 | ₹233.89 | ₹202.74 | ₹283.71 | Sign in for TTM |
| Dividend payout % | — | — | — | 6.0% | 3.9% | 4.3% | 6.9% | 4.2% | Sign in for TTM |
Sign in for TTM
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2019 | Mar 2020Standalone only | Mar 2021Standalone only | Mar 2022Standalone only | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 13 Cr | 13 Cr | 13 Cr | 13 Cr | 13 Cr | 13 Cr | 13 Cr | 13 Cr |
| Reserves | 686 Cr | 0.0000 Cr | 773 Cr | 0.0000 Cr | 980 Cr | 1,269 Cr | 1,511 Cr | 1,861 Cr |
| Borrowings | 210 Cr | 246 Cr | 145 Cr | 231 Cr | 122 Cr | 83 Cr | 45 Cr | 36 Cr |
| Other liabilities | 221 Cr | 279 Cr | 397 Cr | 316 Cr | 464 Cr | 467 Cr | 610 Cr | 1,020 Cr |
| Total liabilities | 1,130 Cr | 1,230 Cr | 1,324 Cr | 1,382 Cr | 1,580 Cr | 1,833 Cr | 2,180 Cr | 2,930 Cr |
| Fixed assets (net) | 230 Cr | 337 Cr | 402 Cr | 457 Cr | 457 Cr | 523 Cr | 674 Cr | 892 Cr |
| CWIP | 104 Cr | 24 Cr | 17 Cr | 20 Cr | 41 Cr | 46 Cr | 45 Cr | 209 Cr |
| Investments | 8 Cr | 8 Cr | 6 Cr | 4 Cr | 0.52 Cr | 1 Cr | 109 Cr | 2 Cr |
| Other assets | 453 Cr | 514 Cr | 548 Cr | 581 Cr | 761 Cr | 921 Cr | 1,139 Cr | 1,483 Cr |
| Total assets | 1,130 Cr | 1,230 Cr | 1,324 Cr | 1,382 Cr | 1,580 Cr | 1,833 Cr | 2,180 Cr | 2,930 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2019 | Mar 2020Standalone only | Mar 2021Standalone only | Mar 2022Standalone only | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | — | — | — | 59 Cr | 237 Cr | 261 Cr | 317 Cr | 347 Cr |
| Cash from investing | — | — | — | -94 Cr | -61 Cr | -150 Cr | -298 Cr | -424 Cr |
| Cash from financing | — | — | — | 38 Cr | -136 Cr | -69 Cr | 25 Cr | 21 Cr |
| Net cash flow | — | — | — | 3 Cr | 40 Cr | 42 Cr | 44 Cr | -56 Cr |
| Free cash flow (OCF − Capex) | — | — | — | -37 Cr | 172 Cr | 120 Cr | 111 Cr | -43 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2019 | Mar 2020Standalone only | Mar 2021Standalone only | Mar 2022Standalone only | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| ROCE % | 3.6% | 577.5% | 15.7% | 741.5% | 19.6% | 29.5% | 22.6% | 26.9% |
| ROE % | 2.4% | 0.0% | 10.3% | 0.0% | 16.4% | 0.0% | 0.0% | 19.4% |
| Debtor days | 90 | 91 | 85 | 90 | 111 | 87 | — | — |
| Inventory days | 195 | 205 | 205 | 221 | 208 | 202 | 244 | 227 |
| Days payable | 123 | 112 | 130 | 98 | 128 | 111 | — | — |
| Cash conversion cycle | 161 | 184 | 160 | 213 | 191 | 179 | 244 | 227 |
| Debt / equity | 0.30 | 0.35 | 0.19 | 0.28 | 0.12 | 0.06 | 0.03 | 0.02 |
| Current ratio | 1.39 | 1.42 | 1.47 | 1.58 | 1.73 | 2.15 | 2.45 | 2.09 |
| Net debt / EBITDA | 3.46 | 0.00 | 0.00 | 0.00 | 0.28 | -0.01 | -0.21 | -0.07 |
Compare with peers
Loading peers…